1. Clinical & Scientific Overview
Epirubicin Hydrochloride (TIP-MED-000557, Reference Code [ONC-08]) is classified under
Oncology & Antineoplastic Medicines as a Anthracycline Cytotoxic Antibiotic • 4'-Epimer Anthracycline Topoisomerase II Inhibitor.
Within the Indian regulatory and compendial framework, it is governed under Schedule H (Prescription Only — Specialist Oncology Supervision).
Pharmorubicin (Pfizer Ltd), Epirubitec (Cipla Ltd), Epichlor (Biocon)
Solution for Injection: 10 mg/5 mL, 50 mg/25 mL, 100 mg/50 mL vials
Oncology Specialisation & Cytotoxic Safety Protocol
Anthracycline Cytotoxic Antibiotic
Antineoplastic Cytotoxic (Vesicant)
Standard Regimen & Cycle Context: 60–100 mg/m2 IV on Day 1 of each 21-day cycle; maximum lifetime cumulative dose: 900 mg/m2 (lower if prior mediastinal radiation).
Signature Dose-Limiting Toxicities & Organ Monitoring: Cumulative dose-dependent dilated cardiomyopathy (congestive heart failure above 900 mg/m2), severe tissue necrosis upon extravasation (potent vesicant — treated with Dexrazoxane or topical DMSO + cold packs), myelosuppression, and harmless red-orange urine discolouration for 1–2 days.
Extravasation, Premedication & Safe Cytotoxic Handling: Verify baseline LVEF by 2D-Echo/MUGA; track lifetime cumulative anthracycline dose in patient oncology passport; administer via free-flowing central line or newly sited peripheral IV and warn patient about red urine.
3. Mechanism of Action & Pharmacodynamics
4'-hydroxyl epimer of doxorubicin that intercalates DNA base pairs, stabilizes the Topoisomerase II-DNA cleavable complex causing double-strand breaks, and generates iron-mediated free radicals; undergoes faster hepatic glucuronidation than doxorubicin, resulting in lower cardiotoxicity per milligram.
4. Therapeutic Indications & Evidence-Supported Uses
- Adjuvant and metastatic Breast Cancer (FEC / EC-T regimens)
- Perioperative Gastric and Oesophageal Carcinoma (FLOT / ECF)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Educational Oncology Regimen Context (Specialist Reference Only): 60–100 mg/m2 IV on Day 1 of each 21-day cycle; maximum lifetime cumulative dose: 900 mg/m2 (lower if prior mediastinal radiation).
Administration & Meal Timing: 60–100 mg/m2 IV on Day 1 of each 21-day cycle; maximum lifetime cumulative dose: 900 mg/m2 (lower if prior mediastinal radiation).
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Specialist oncology pharmacokinetic profile; dosing depends on Body Surface Area (BSA in m2), Calvert GFR formula, or flat targeted dosing with strict organ-function adjustments.
Hepatic enzymatic activation/inactivation or proteolytic degradation (for monoclonal antibodies); see specific polymorphism and interaction notes.
Verify serum creatinine and eGFR before every cycle; see drug-specific renal dosing and uroprotection rules.
Check total bilirubin, AST, and ALT prior to each cycle; taxanes, anthracyclines, and TKIs require strict hepatic dose modification.
7. Contraindications, Precautions & High-Risk Warnings
- Severe hypersensitivity to Epirubicin or formulation vehicle
- Pregnancy and lactation (potent teratogen/embryotoxic class warning unless explicitly evaluated by oncology specialist)
- Severe unrecovered bone marrow aplasia or decompensated organ failure per protocol thresholds
Key Clinical Precautions: Cumulative dose-dependent dilated cardiomyopathy (congestive heart failure above 900 mg/m2), severe tissue necrosis upon extravasation (potent vesicant — treated with Dexrazoxane or topical DMSO + cold packs), myelosuppression, and harmless red-orange urine discolouration for 1–2 days.
8. Adverse Effects Profile
- Cumulative dose-dependent dilated cardiomyopathy (congestive heart failure above 900 mg/m2), severe tissue necrosis upon extravasation (potent vesicant — treated with Dexrazoxane or topical DMSO + cold packs), myelosuppression, and harmless red-orange urine discolouration for 1–2 days.
- Cumulative dose-dependent dilated cardiomyopathy (congestive heart failure above 900 mg/m2), severe tissue necrosis upon extravasation (potent vesicant — treated with Dexrazoxane or topical DMSO + cold packs), myelosuppression, and harmless red-orange urine discolouration for 1–2 days.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Cumulative dose-dependent dilated cardiomyopathy (congestive heart failure above 900 mg/m2), severe tissue necrosis upon extravasation (potent vesicant — treated with Dexrazoxane or topical DMSO + cold packs), myelosuppression, and harmless red-orange urine discolouration for 1–2 days.
- Avoid live-attenuated vaccines during immunosuppressive chemotherapy; verify CYP3A4, UGT1A1, DPD, and QTc interactions before each cycle.
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Verify baseline LVEF by 2D-Echo/MUGA; track lifetime cumulative anthracycline dose in patient oncology passport; administer via free-flowing central line or newly sited peripheral IV and warn patient about red urine.
Pharmacist Patient Counselling Points:
- Verify baseline LVEF by 2D-Echo/MUGA; track lifetime cumulative anthracycline dose in patient oncology passport; administer via free-flowing central line or newly sited peripheral IV and warn patient about red urine.
- Report fever >=38.0°C (100.4°F) immediately (medical emergency: possible febrile neutropenia).
- Follow strict reproductive contraception and safe cytotoxic oral handling instructions.
Storage, Stability & Dispensing Safeguards: Verify baseline LVEF by 2D-Echo/MUGA; track lifetime cumulative anthracycline dose in patient oncology passport; administer via free-flowing central line or newly sited peripheral IV and warn patient about red urine.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: National Cancer Grid (NCG) India Consensus Guidelines; NLEM 2022 Antineoplastic Section; Indian Pharmacopoeia (IP) & CDSCO Approved Oncology Prescribing Information.
Official Verification Portals: National Cancer Grid (NCG) India — Evidence-Based Oncology Guidelines • CDSCO — Central Drugs Standard Control Organization Approved Drug Data • Indian Pharmacopoeia Commission (IPC)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [ONC-07] Pemetrexed Disodium — Antimetabolite (Folate Antagonist) • Multi-Targeted Antifolate An
- [ONC-09] Daunorubicin Hydrochloride — Anthracycline Cytotoxic Antibiotic • Anthracycline Antileukaemic
- [ONC-10] Bleomycin Sulfate — Antitumour Antibiotic (G2/M Phase Specific) • Glycopeptide Radiom
- [ONC-11] Carboplatin — Platinum Alkylating-Like Agent • Second-Generation Platinum Coord
